TACT833

Last updated

TACT833
Clinical data
Other namesTACT-833
Drug class Monoamine transporter modulator; Serotonin 5-HT1B receptor modulator
ATC code
  • None

TACT833 is a monoamine transporter modulator and serotonin 5-HT1B receptor modulator which is under development for the treatment of alcohol use disorder, anorexia, and binge-eating disorder. [1] [2] [3] [4] It is being developed by Tactogen. [1] [2] [3] [4] As of the first quarter of 2025, the drug is in the preclinical research stage of development. [1] [2] [3] The exact chemical structure of TACT833 does not yet appear to have been disclosed, [4] but it may be a benzofuran like 5-MAPB, 6-MAPB, BK-5-MAPB, or BK-6-MAPB. [5]

See also

References

  1. 1 2 3 "Delving into the Latest Updates on TACT411/833 with Synapse". Synapse. 14 June 2025. Retrieved 25 November 2025.
  2. 1 2 3 Haichin M (2024). "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 29 January 2025.
  3. 1 2 3 "Tactogen Inc – Pipeline". Tactogen Inc. Retrieved 29 January 2025. OUR PIPELINE: [...] COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Alcohol Use Disorder. Prevalence: 13.9%. STATUS: Preclinical. COMPOUND: TACT411/833*. TARGETS: 5-HT1B & MATs. INDICATION: Anorexia / Binge Eating Disorder. Prevalence: 3.6%. STATUS: Preclinical. [...] *We will make a final decision among our lead candidates after completing IND-enabling studies. Alternate lead candidates include TACT 523.
  4. 1 2 3 Matthew Baggott, Tactogen (14 November 2025). Progress in Novel Entactogens as Therapeutics. 5th Annual Conference on Psychedelics and Psychedelic Medicine, Virtual, November 14-15, 2025. Massachusetts General Hospital. Archived from the original on 8 August 2025. Retrieved 25 November 2025.{{cite conference}}: CS1 maint: bot: original URL status unknown (link)
  5. ↑ US 20230150963, Matthew Baggott,"Advantageous benzofuran compositions for mental disorders or enhancement",published 2023 May 18, assigned to Tactogen
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.